Cellectis CEO André Choulika to serve as chairman
This article was originally published in Scrip
Executive Summary
Cellectis, a French genome engineering specialist, has appointed its CEO, André Choulika, chairman, taking over from Christian Policard who was previously chairman for six years, and who will stay on as a director. Dr Choulika was the founder of Cellectis, and has been the company's CEO since its inception.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.